Characterization of metabolites in infiltrating gliomas using ex vivo 1H high-resolution magic angle spinning spectroscopy

NMR in Biomedicine

Volumn 27, Issue 5, 2014, Pages 578-593

  Elkhaled, Adam ^a,b   Jalbert, Llewellyn ^a,b   Constantin, Alexandra ^b,c   Yoshihara, Hikari A I ^b,d   Phillips, Joanna J ^b   Molinaro, Annette M ^b   Chang, Susan M ^b   Nelson, Sarah J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

2 hydroxyglutarate; Glioma; Image guided biopsy; Malignant transformation; Metabolite profiling

Indexed keywords

BIOMOLECULES; GRADING; METABOLITES; PATIENT TREATMENT;

2-HYDROXYGLUTARATE; GLIOMA; IMAGE-GUIDED; MALIGNANT TRANSFORMATIONS; METABOLITE PROFILING;

TUMORS;

CHOLINE; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; PHOSPHORYLCHOLINE;

ACCURACY; ARTICLE; BLOOD BRAIN BARRIER; EX VIVO STUDY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; METABOLITE; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROTON HIGH RESOLUTION MAGIC ANGLE SPINNING SPECTROSCOPY; RECURRENT DISEASE; SPECTROSCOPY; BRAIN TUMOR; CANCER GRADING; METABOLISM; METABOLOME; PATHOLOGY; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

BRAIN NEOPLASMS; GLIOMA; HUMANS; LOGISTIC MODELS; METABOLOME; NEOPLASM GRADING; PROTON MAGNETIC RESONANCE SPECTROSCOPY; ROC CURVE;

EID: 84897960611     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3097     Document Type: Article

References (46)

1. Lois DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2): 97-109.
2. Lopes MBS, VandenBerg SR, Scheithauer BW. The World Health Organization classification of nervous system tumors in experimental neuro-oncology. In Levine AJ, Schmidek HH (eds). Molecular Genetics of Nervous System Tumors. Wiley-Liss: New York; 1993, pp. 1-36.
3. Jaeckle KA, Decker PA, Ballman KV, Flynn PJ, Giannini C, Scheithauer BW, Jenkins RB, Bucknew JC. Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J. Neurooncol. 2011; 104(1): 253-259.
4. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat. Rev. Cancer 2011; 11(12): 835-848.
5. Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ. Cooperativity within and among Pten, p53, Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 2011; 19(3): 305-316.
6. Philips HS, Kharbanda S, Chen R, Forrest WF, Sorian RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BF, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9(3): 157-173.
7. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir B, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennen C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. The Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
8. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HAI, Parvataneni R, Srinivasan R, Bourne G, Berger MS, Chang SM, Cha S, Nelson SJ. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci. Transl. Med. 2012; 4: 116ra5.
9. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorenson GS. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci. Transl. Med. 2012; 4: 116ra4.
10. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009; 360: 765-773.
11. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam D, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
12. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75: 1560-1566.
13. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010; 120: 707-718.
14. 1H MR spectroscopic imaging with flyback echo-planar readout for glioma patients. Ann. Biomed. Eng. 2011; 39: 193-204.
15. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative diffusion-tensor MRI. J. Magn. Reson. B, 1996; 111: 209-219.
16. McKnight TR, Noworolski SM, Vigneron DB, Nelson SJ. An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J. Magn. Reson. Imaging 2001; 13: 167-177.
17. 1H HR-MAS spectroscopy of prostate tissue. Magn. Reson. Med. 2009; 61: 525-532.
18. Stefan D, Cesare FD, Andrasescu A, Popa E, Lazariev A, Vescovo E, Strbak O, Williams S, Starcuk Z, Cabanas M, van Ormondt D, Graveron-Demily D. Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package. Meas. Sci. Technol. 2009; 20: 104035(9pp).
19. Ratiney H, Albers MJ, Rabeson H, Kurhanewicz J. Semi-parametric time-domain quantification of HR-MAS data from prostate tissue. NMR Biomed. 2010; 23: 1-13.
20. 1H NMR. NMR Biomed. 2008; 21(10): 1138-1147.
21. 1H HR-MAS metabolite measurements in adult human gliomas. J. Magn. Reson. Imaging 2010; 31: 289-297.
22. Constantin A, Elkhaled A, Jalbert L, Srinivasan R, Cha S, Chang SM, Bajcsy R, Nelson SJ. Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy. Artif. Intell. Med. 2012; 55(1): 61-70.
23. Vettukattil R, Gulati M, Sjobakk TE, Jakola AS, Kvernmo NA, Torp SH, Bathen TF, Gulati S, Gribbestad IS. Differentiating diffuse World Health Organization grade II and IV astrocytomas with ex vivo magnetic resonance spectroscopy. Neurosurgery 2013; 72(2): 186-195.
24. Sjobakk TE, Vettukattil R, Gulati M, Gulati S, Lundgren S, Gribbestad IS, Torp SH, Bathen TF. Metabolic profiles of brain metastases. Int. J. Mol. Sci. 2013; 14(1): 2104-2118.
25. 1H MRS study of human high grade gliomas. NMR Biomed. 2004; 17(4): 191-205.
26. 1H NMR spectroscopy. J. Neurochem. 1995; 64(4): 1655-1661.
27. 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR Biomed. 2009; 22: 629-637.
28. Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro-Oncol. 2010; 12: 1152-1161.
29. 1H MRS. Magn. Reson. Med. 2003; 49: 632-637.
30. Thelwal PE, Yemin AY, Gillian TL, Simpson NE, Kasibhatla MS, Rabbani ZN, MacDonald JM, Blackband SJ, Gamcsik MP. Noninvasive in vivo detection of glutathione metabolism in tumors. Cancer Res. 2005; 65: 10149-10153.
31. Srinivasan R, Ratiney H, Hammond-Rosenbluth KE, Pelletier D, Nelson SJ. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn. Reson. Imaging 2010; 28(2): 163-170.
32. Choi C, Ganji SK, DeBerardinis RJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Taisanen JM, Marin-Valencia I, Pascual JM, Madden CJ, Mickey BE, Malloy CR, Bachoo RM, Maher EA. 2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 2012; 18(4): 624-629.
33. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J. Neurooncol. 2012; 107(1): 197-205.
34. 1H NMR spectroscopy in vivo and in vitro. J. Neurochem. 1994; 63(4): 1538-1543.
35. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12: 413-439.
36. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro-Oncol. 2012; 14(3): 315-325.
37. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of taurine, hypotaurine and their metabolic precursor. Biochem. J. 1988; 256(1): 251-255.
38. Brand A, Leibfritz D, Hamprecht B, Dringen R. Metabolism of cysteine in astroglial cells: synthesis of hypotaurine and taurine. J. Neurochem. 1998; 71: 827-832.
39. Wright AJ, Fellows GA, Griffiths JR, Wilson M, Bell BA, Howe FA. Ex vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers. Molec. Cancer, 2010; 9: 66.
40. Presner JR, Chinaiyan AM. Metabolism unhinged: IDH mutations in cancer. Nat. Med. 2011; 17: 291-293.
41. Righi V, Andronesi OC, Mintzopoulos D, Black PM, Tzika AA. High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. Int. J. Oncol. 2010; 36(2): 301-306.
42. Chang SM, Nelson SJ, Vandenberg S, Cha S, Prados M, Butowski N, McDermott M, Parsa AT, Aghi M, Clarke J, Berger M. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J. Neurooncol. 2009; 92(3): 401-415.
43. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J. Neurooncol. 2009; 91(1): 69-81.
44. 2 metabolite relaxation times in glioma and normal brain at 3T. J. Magn. Reson. Imaging 2008; 28(2): 342-350.
45. Chawla S, Oleaga L, Wang S, Krejza J, Woo JH, O'Rourke DM, Judy KD, Grady MS, Melhem ER, Poptani H. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas and astrocytomas. J. Neuroimaging 2010; 20(1): 3-8.
46. Huang J, Gholami B, Agar NYR, Norton I, Haddad WM, Tannenbaum AR. Classification of astrocytomas and oligodendrogliomas from mass spectrometry data using sparse kernel machines. Engineering in Medicine and Biology Society, EMBC, Annual International Conference of the IEEE, Boston, Massachusetts, USA, 2011; 7965-7968.